American Century Companies Inc. Buys 84,934 Shares of ADMA Biologics Inc $ADMA

American Century Companies Inc. boosted its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 1.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,695,923 shares of the biotechnology company’s stock after purchasing an additional 84,934 shares during the period. American Century Companies Inc.’s holdings in ADMA Biologics were worth $68,842,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the stock. Westfield Capital Management Co. LP bought a new stake in shares of ADMA Biologics during the 3rd quarter worth approximately $74,866,000. Thrivent Financial for Lutherans grew its stake in shares of ADMA Biologics by 78.1% in the second quarter. Thrivent Financial for Lutherans now owns 3,315,425 shares of the biotechnology company’s stock valued at $60,373,000 after buying an additional 1,453,924 shares in the last quarter. Franklin Resources Inc. increased its holdings in ADMA Biologics by 66.4% during the second quarter. Franklin Resources Inc. now owns 2,719,016 shares of the biotechnology company’s stock worth $49,513,000 after buying an additional 1,085,286 shares during the last quarter. First Light Asset Management LLC acquired a new position in ADMA Biologics during the second quarter worth $17,338,000. Finally, Ranger Investment Management L.P. raised its position in ADMA Biologics by 49.1% during the second quarter. Ranger Investment Management L.P. now owns 2,390,375 shares of the biotechnology company’s stock worth $43,529,000 after acquiring an additional 786,865 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Price Performance

Shares of ADMA opened at $16.54 on Thursday. The company’s 50-day moving average is $17.07 and its 200-day moving average is $16.80. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. The firm has a market capitalization of $3.94 billion, a PE ratio of 27.57 and a beta of 0.51. ADMA Biologics Inc has a fifty-two week low of $13.76 and a fifty-two week high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.20. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The firm had revenue of $139.16 million during the quarter, compared to the consensus estimate of $139.80 million. During the same period last year, the business posted $0.46 earnings per share. The business’s revenue for the quarter was up 18.4% compared to the same quarter last year. Equities analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on ADMA shares. Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. Finally, Zacks Research upgraded ADMA Biologics from a “hold” rating to a “strong-buy” rating in a report on Monday. Two analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $32.00.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.